Journal
INTENSIVE CARE MEDICINE
Volume 38, Issue 10, Pages 1588-1598Publisher
SPRINGER
DOI: 10.1007/s00134-012-2624-y
Keywords
Receptor for advanced glycation end products; Acute lung injury; Acute respiratory distress syndrome; Damage-associated molecular patterns
Categories
Funding
- NHLBI NIH HHS [R01 HL048889] Funding Source: Medline
Ask authors/readers for more resources
The receptor for advanced glycation end products (RAGE) is a pattern-recognition receptor and evolutionary member of the immunoglobulin superfamily that is involved in the host response to infection, injury, and inflammation. It exists in two forms: membrane-bound and soluble forms (sRAGE). RAGE recognizes a variety of ligands and, via a receptor-driven signaling cascade, activates the transcription factor NF-kappa B, leading to the expression of proinflammatory cytokines. The soluble form, sRAGE, is a decoy receptor and competitively inhibits membrane RAGE activation. RAGE is constitutively expressed abundantly in the lung under basal conditions. This expression is enhanced during inflammatory states such as with acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). This review summarizes the characteristics of RAGE, RAGE isoforms, RAGE ligands, and signaling pathways in the pathogenesis of ALI and ARDS. Additionally, the review explores the potential of RAGE as an important therapeutic target in ALI/ARDS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available